Effects of 12 mg vs. 6 mg dexamethasone on thromboembolism and bleeding in patients with critical COVID-19 - a post hoc analysis of the randomized, blinded COVID STEROID 2 trial.
Sandra JonmarkerFelix AlarcónJacob LitorellAnders GranholmEva Joelsson AlmMichelle ChewLene RussellSarah WeiheEmilie Kabel MadsenNick MeierJens Wolfgang LeistnerJohan MårtenssonJacob HollenbergAnders PernerMaj-Brit Nørregaard KjærMarie Warrer MunchMartin DahlbergMaria CronhjortRebecka Rubenson WahlinPublished in: Annals of intensive care (2023)
Among patients with critical COVID-19, 12 mg vs. 6 mg dexamethasone daily did not result in a statistically significant difference in the composite outcome of death or thromboembolism. However, uncertainty remains due to the limited number of patients.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- phase iii
- low dose
- newly diagnosed
- ejection fraction
- study protocol
- high dose
- phase ii
- chronic kidney disease
- respiratory syndrome coronavirus
- clinical trial
- open label
- peritoneal dialysis
- randomized controlled trial
- atrial fibrillation
- physical activity
- patient reported